A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Cancer Survivors, Healthy Participant, Elderly
In brief
This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system), metabolic dysfunction, and gut-brain-muscle axis dysregulation.
Key facts
- Study ID
- NCT07363057
- Run by
- GI Innovation, Inc.
- People needed
- 15
- Starts
- 2026-01-01
- Expected to finish
- 2026-10-01
- Last updated by the study team
- 2026-01-26
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- Novatrials — Charlestown, New South Wales, Australia (enrolling)
- Southern Oncology Clinical Research Unit — Adelaide, South Australia, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.